---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-001557"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2022-01-19T23:59:59+00:00"
generated_at: "2026-06-27T17:20:05.128504+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma announces positive interim safety data: 100% IMX-110 treatment cycle completion in Phase 1b/2a trial

## Summary
- 100% of patients completed planned treatment cycles with IMX-110 without drug-related interruptions in ongoing Phase 1b/2a trial.
- Historical comparators for approved soft tissue sarcoma drugs show 43-67% completion rates (Demetri et al., 2015; Schöffski et al., 2016).
- IMX-110 has FDA Orphan Drug Designation for soft tissue sarcoma and Rare Pediatric Disease Designation for rhabdomyosarcoma.
- Immix Biopharma (NASDAQ: IMMX) is developing IMX-110 as monotherapy for soft tissue sarcoma, a $3B market targeting $6.5B by 2030.

## SEC filing metadata
- accession: 0001493152-22-001557
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2022-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315222001557/0001493152-22-001557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315222001557/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-001557
- JSON: https://secwatch.observer/filing/0001493152-22-001557.json
- Plain text: https://secwatch.observer/filing/0001493152-22-001557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.